Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Naja naja atra venom** is the crude venom derived from the Chinese cobra (Naja atra, formerly Naja naja atra), a cobra species native to southern China and neighboring regions. The venom is a complex mixture of bioactive peptides and proteins, including **cardiotoxins**, **cobratoxin (neurotoxin alpha-cobratoxin)**, **cobra venom factor**, **phospholipase A2**, and other enzymatic/non-enzymatic proteins. Medically, the crude venom—or fractions of it—has been studied primarily in animal models for its **anti-inflammatory** and **immunomodulatory** effects. Notably, research in mice has shown that oral administration of naja naja atra venom can protect against manifestations of systemic lupus erythematosus by reducing proteinuria, attenuating lymphadenopathy, decreasing inflammatory cytokines (IL-6, TNF-alpha), and modulating immune complex deposition and organ pathology[1]. Some studies have also suggested a protective effect in models of nephropathy and rheumatoid arthritis[1]. However, as a crude venom, it is not an approved pharmaceutical drug but rather a biological mixture of investigational and traditional medicine interest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naja naja atra venom.